Elizabeth R. Rayburn - Search Results

Year	Number of Results
2005	5
2006	5
2007	4
2008	3
2009	9
2010	4
2011	1
2012	1
2016	1
2017	3
2018	2
2024	0

1

FDA-approved medications that impair human spermatogenesis.

Ding J, Shang X, Zhang Z, Jing H, Shao J, Fei Q, Rayburn ER, Li H. Ding J, et al. Among authors: rayburn er. Oncotarget. 2017 Feb 7;8(6):10714-10725. doi: 10.18632/oncotarget.12956. Oncotarget. 2017. PMID: 27801671 Free PMC article. Review.

2

FDA-approved drugs that interfere with laboratory tests: A systematic search of US drug labels.

Yao H, Rayburn ER, Shi Q, Gao L, Hu W, Li H. Yao H, et al. Among authors: rayburn er. Crit Rev Clin Lab Sci. 2017 Jan;54(1):1-17. doi: 10.1080/10408363.2016.1191425. Epub 2016 Jun 27. Crit Rev Clin Lab Sci. 2017. PMID: 27193822 Review.

3

Antisense, RNAi, and gene silencing strategies for therapy: mission possible or impossible?

Rayburn ER, Zhang R. Rayburn ER, et al. Drug Discov Today. 2008 Jun;13(11-12):513-21. doi: 10.1016/j.drudis.2008.03.014. Epub 2008 May 3. Drug Discov Today. 2008. PMID: 18549978 Free PMC article. Review.

4

Recent advances in validating MDM2 as a cancer target.

Rayburn ER, Ezell SJ, Zhang R. Rayburn ER, et al. Anticancer Agents Med Chem. 2009 Oct;9(8):882-903. doi: 10.2174/187152009789124628. Anticancer Agents Med Chem. 2009. PMID: 19538162 Free PMC article. Review.

5

Oncogenes as novel targets for cancer therapy (part III): transcription factors.

Zhang Z, Li M, Rayburn ER, Hill DL, Zhang R, Wang H. Zhang Z, et al. Among authors: rayburn er. Am J Pharmacogenomics. 2005;5(5):327-38. doi: 10.2165/00129785-200505050-00005. Am J Pharmacogenomics. 2005. PMID: 16196502 Review.

6

FDA-approved drugs that are spermatotoxic in animals and the utility of animal testing for human risk prediction.

Rayburn ER, Gao L, Ding J, Ding H, Shao J, Li H. Rayburn ER, et al. J Assist Reprod Genet. 2018 Feb;35(2):191-212. doi: 10.1007/s10815-017-1062-8. Epub 2017 Oct 24. J Assist Reprod Genet. 2018. PMID: 29063992 Free PMC article. Review.

7

The need for contraception in patients taking prescription drugs: a review of FDA warning labels, duration of effects, and mechanisms of action.

Zhang Z, Xu L, Zhang Z, Ding H, Rayburn ER, Li H. Zhang Z, et al. Among authors: rayburn er. Expert Opin Drug Saf. 2018 Dec;17(12):1171-1183. doi: 10.1080/14740338.2018.1544617. Epub 2018 Nov 9. Expert Opin Drug Saf. 2018. PMID: 30394114 Review.

8

RYBP stabilizes p53 by modulating MDM2.

Chen D, Zhang J, Li M, Rayburn ER, Wang H, Zhang R. Chen D, et al. Among authors: rayburn er. EMBO Rep. 2009 Feb;10(2):166-72. doi: 10.1038/embor.2008.231. Epub 2008 Dec 19. EMBO Rep. 2009. PMID: 19098711 Free PMC article.

9

Anti-Inflammatory Agents for Cancer Therapy.

Rayburn ER, Ezell SJ, Zhang R. Rayburn ER, et al. Mol Cell Pharmacol. 2009;1(1):29-43. doi: 10.4255/mcpharmacol.09.05. Mol Cell Pharmacol. 2009. PMID: 20333321 Free PMC article.

10

Oncogenes as novel targets for cancer therapy (part II): Intermediate signaling molecules.

Zhang Z, Li M, Rayburn ER, Hill DL, Zhang R, Wang H. Zhang Z, et al. Among authors: rayburn er. Am J Pharmacogenomics. 2005;5(4):247-57. doi: 10.2165/00129785-200505040-00005. Am J Pharmacogenomics. 2005. PMID: 16078861 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

31 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

31 results

Results by year